Table 20.
Summary of Evidence for Fracture Risk Reduction
| Fracture risk reduction | |||
|---|---|---|---|
| Drug | Vertebral | Nonvertebral | Hip |
| Calcitonin (Miacalcin, Fortical) | Yes | No effect demonstrateda | No effect demonstrateda |
| Raloxifene (Evista) | Yes | No effect demonstrateda | No effect demonstrateda |
| Ibandronate (Boniva) | Yes | No effect demonstrateda | No effect demonstrateda |
| Alendronate (Fosamax) | Yes | Yes | Yes |
| Risedronate (Actonel) | Yes | Yes | Yes |
| Zoledronic acid (Reclast) | Yes | Yes | Yes |
| Denosumab (Prolia) | Yes | Yes | Yes |
| Teriparatide (Forteo) | Yes | Yes | No effect demonstrateda |
a
The lack of demonstrable effect at these sites should be considered in the context that the studies may not have been adequately powered.